Nuwellis, Inc.NUWEEarnings & Financial Report
Nuwellis, Inc. is a US-based medical technology firm that develops, manufactures and sells specialized fluid management solutions for clinical use. Its core products serve critical care, nephrology and dialysis segments, with main markets in North America and select European regions, supporting better outcomes for patients with fluid overload.
NUWE Q4 FY2025 Key Financial Metrics
Revenue
$2.4M
Gross Profit
$1.7M
Operating Profit
$-2.4M
Net Profit
$-2.4M
Gross Margin
68.2%
Operating Margin
-100.8%
Net Margin
-99.9%
YoY Growth
4.4%
EPS
$35.73
Nuwellis, Inc. Q4 FY2025 Financial Summary
Nuwellis, Inc. reported revenue of $2.4M (up 4.4% YoY) for Q4 FY2025, with a net profit of $-2.4M (down 65.0% YoY) (-99.9% margin). Cost of goods sold was $770.0K, operating expenses totaled $4.1M.
Key Financial Metrics
| Total Revenue | $2.4M |
|---|---|
| Net Profit | $-2.4M |
| Gross Margin | 68.2% |
| Operating Margin | -100.8% |
| Report Period | Q4 FY2025 |
Nuwellis, Inc. Annual Revenue by Year
Nuwellis, Inc. annual revenue history includes year-by-year totals (for example, 2025 revenue was $8.3M).
Nuwellis, Inc. Quarterly Revenue & Net Profit History
Nuwellis, Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $2.4M | +4.4% | $-2.4M | -99.9% |
| Q3 FY2025 | $2.2M | -6.3% | $468.0K | 21.1% |
| Q2 FY2025 | $1.7M | -21.4% | $-12.6M | -727.7% |
| Q1 FY2025 | $1.9M | +2.5% | $-3.0M | -158.3% |
| Q4 FY2024 | $2.3M | -9.0% | $-1.5M | -63.2% |
| Q3 FY2024 | $2.4M | -1.9% | $2.4M | 99.6% |
| Q2 FY2024 | $2.2M | +5.7% | $-7.7M | -352.1% |
| Q1 FY2024 | $1.9M | +1.7% | $-4.3M | -233.2% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.9M | $2.2M | $2.4M | $2.3M | $1.9M | $1.7M | $2.2M | $2.4M |
| YoY Growth | 1.7% | 5.7% | -1.9% | -9.0% | 2.5% | -21.4% | -6.3% | 4.4% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $6.7M | $6.2M | $6.7M | $9.9M | $7.0M | $9.2M | $8.0M | $6.1M |
| Liabilities | $5.8M | $13.0M | $3.5M | $3.3M | $3.4M | $18.2M | $4.1M | $3.5M |
| Equity | $885000 | $-6.8M | $3.2M | $6.5M | $3.6M | $-9.0M | $3.9M | $2.6M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-2.9M | $-2.8M | $-2.5M | $-1.5M | $-2.5M | $-2.1M | $-3.1M | $-3.0M |